Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses: 2012-2024

Historic Interest Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $30.3 million.

  • Amphastar Pharmaceuticals' Interest Expenses fell 6.18% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 24.26%. This contributed to the annual value of $30.3 million for FY2024, which is 11.73% up from last year.
  • Amphastar Pharmaceuticals' Interest Expenses amounted to $30.3 million in FY2024, which was up 11.73% from $27.2 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Interest Expenses' 5-year high stood at $30.3 million during FY2024, with a 5-year trough of $374,000 in FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Interest Expenses averaged around $19.8 million, with its median value being $27.2 million (2023).
  • Data for Amphastar Pharmaceuticals' Interest Expenses shows a peak YoY spiked of 1,371.18% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Interest Expenses stood at $374,000 in 2020, then spiked by 136.63% to $885,000 in 2021, then skyrocketed by 108.59% to $1.8 million in 2022, then soared by 1,371.18% to $27.2 million in 2023, then grew by 11.73% to $30.3 million in 2024.